EUVIMEDEUVIMED entdecken
Crossref

Quantification of Monoclonal Antibodies in Pharmaceutical Matrices by Middle‐Up Capillary Zone Electrophoresis‐Mass Spectrometry

Jana Havlikova iD, Katarina Marakova iD, Peter Mikus iD

Journal of Separation Science · 2025

DOI: 10.1002/jssc.70335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Separation Science, 2025. Verfasst von Jana Havlikova und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Infliximab. Die Arbeit nennt 24 Literaturangaben. Gefördert von: VEGA 1/0514/22, EU NextGenerationEU, Recovery and Resilience Plan for Slovakia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibodies are biopharmaceuticals used to treat various diseases, including autoimmune disorders and cancer. Due to their structural complexity and inherent heterogeneity, robust analytical methods are required for their accurate quantification and quality control. This study presents a novel middle‐up (MU) capillary zone electrophoresis‐mass spectrometry (CZE‐MS) method for the quantitative analysis of infliximab (IFX), a widely used therapeutic mAb. The method relies on disulfide bond reduction to separate heavy and light chains, followed by CZE separation using a 2 M acetic acid background electrolyte and MS detection in single ion monitoring mode. Adalimumab was used as an internal standard, providing a suitable alternative to isotopically labeled monoclonal antibody analogues. Evaluation of the analytical method performance followed ICH Q2(R1) guidelines and demonstrated an acceptable linearity range (4–35 µg/mL), precision, accuracy, and a limit of quantification of 4 µg/mL. The method was successfully applied to quantify IFX in a commercial pharmaceutical (Remicade). Moreover, the method was preliminarily tested for the quality control of bevacizumab in Avastin and rituximab in MabThera pharmaceutical formulations. To our knowledge, this is the first report of quantitative MU CZE‐MS analysis of therapeutic monoclonal antibodies directly from pharmaceutical matrices, highlighting its potential for quality drug control applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalInfliximabElectrophoresis, CapillaryMass SpectrometryRituximabBevacizumab

Stichwörter der Autor:innen

biopharmaceuticalsinfliximabmass spectrometrymiddle‐upproteins

Substanzen

Antibodies, MonoclonalInfliximabRituximabBevacizumab

Autor:innen und Institutionen

  • Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia.
  • Toxicology and Antidoping Centre, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia.

ORCID-Profile: Jana Havlikova, Katarina Marakova, Peter Mikus

Förderung

  • VEGA 1/0514/22
  • EU NextGenerationEU
  • Recovery and Resilience Plan for Slovakia

Zitieren

APA

Havlikova, J., Marakova, K., & Mikus, P. (2025). Quantification of Monoclonal Antibodies in Pharmaceutical Matrices by Middle‐Up Capillary Zone Electrophoresis‐Mass Spectrometry. Journal of Separation Science. https://doi.org/10.1002/jssc.70335

Vancouver

Havlikova J, Marakova K, Mikus P. Quantification of Monoclonal Antibodies in Pharmaceutical Matrices by Middle‐Up Capillary Zone Electrophoresis‐Mass Spectrometry. Journal of Separation Science. 2025. doi:10.1002/jssc.70335

BibTeX
@article{Havlikova2025,
  author = {Havlikova, Jana and Marakova, Katarina and Mikus, Peter},
  title = {Quantification of Monoclonal Antibodies in Pharmaceutical Matrices by Middle‐Up Capillary Zone Electrophoresis‐Mass Spectrometry},
  journal = {Journal of Separation Science},
  year = {2025},
  doi = {10.1002/jssc.70335}
}
Kostenlos starten →